Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
Table 1
Timeline of treatment.
Treatment
Dose and frequency
Timeline (month/year)
Reason for cessation
Months of therapy
Vemurafenib
960 mg (4 × 240 mg) orally twice daily (BID)
4/2012–9/2014
Progression
29
Ipilimumab
4 cycles induction q3 weeks at 3 mg/kg, followed by maintenance treatment